Sign in
EWTX Stock Price, Chart, Stats & News
Edgewise Therapeutics, Inc.
Save
4.18B
Market cap
–
Current P/E
–
Forward P/E
EWTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -30.36% |
ROE | -31.97% |
D/E | 0.01x |
Interest coverage ratio | – |
EWTX valuation
P/E | – |
P/S | – |
P/B | 6.08x |
P/CF | -22.07x |
P/FCF | -23.00x |
P/OCF | -22.07x |
PEG | 5.98x |
EV multiple | -18.75x |
About
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial.
Similar securities
Based on sector and market capitalization
Report issue